FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Biosimilar User Fee Reauthorization Meeting

Federal Register notice: FDA announces an 11/19 virtual public meeting on reauthorizing the Biosimilar User Fee Act program.

Federal Register

Guidance on Nonclinical Testing for Nicotine Products

Federal Register notice: FDA makes available a final guidance on inhaled nicotine product nonclinical testing.

Medical Devices

Cleaning Method Deviations Could Impair Sigma Pump: Baxter

FDA says Baxter is reminding customers that deviations from prescribed cleaning methods for Sigma Spectrum infusion pumps could hurt pump functionalit...

Human Drugs

Timely PSGs Can Spur ANDA Submissions: CDER Research

CDER analyzes factors that contribute to an increased likelihood of ANDA submissions for NCE and non-NCE innovator drugs.

Human Drugs

FDA Enhancements Sought for Model-Informed Drug Development

FDA pitches a plan to enhance its Model-Informed Drug Development (MIDD) activities under the next iteration of its Prescription Drug User Fee Act pro...

Human Drugs

FDA Inks Agreement with SomaLogic for Proteomics Study

FDA signs a five-year agreement with SomaLogic to study using proteomics to identify biomarkers that may be useful in demonstrating biosimilarity of a...

Medical Devices

Strained by Covid, CDRH Wants More MDUFA Money

CDRH seeks a boost to its resources as it negotiates the reauthorization of the Medical Device User Fee Act (MDUFA) program, claiming Covid-19 is taki...

Animal Drugs

Med-Pharmx Selling Adulterated Animal Drugs: DoJ

The Justice Department asks a California federal court for an injunction to prevent Med-Pharmx from manufacturing and distributing adulterated animal ...

Orally Inhaled Nicotine Drug Product Nonclinical Testing

FDA issues a guidance on nonclinical information to support the development and approval of orally inhaled nicotine-containing drug products.

Human Drugs

Praise for Nervous System Metastases Draft Guidance

Four drug companies recommend technical changes to an FDA draft guidance on evaluating cancer drugs in patients with central nervous system metastases...